Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in advanced solid tumors with bone metastases
NCT01588821Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in solid tumor, sponsored by Massachusetts General Hospital. Primary endpoint: Number of Participants With Bone Bio-marker Response at 8 weeks. Started Jun 2012; status: completed.
02
Drugs
cabozantinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01588821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588821.